Welcome to our dedicated page for EAGLE PHARMS news (Ticker: EGRX), a resource for investors and traders seeking the latest updates and insights on EAGLE PHARMS stock.
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) is a leading specialty pharmaceutical company committed to the development and commercialization of innovative injectable products targeted at critical care, orphan diseases, and oncology. The company’s robust portfolio includes four FDA-approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. Eagle is also advancing multiple product candidates through late-stage development, with several under review by the Food and Drug Administration (FDA).
Recently, Eagle achieved a significant regulatory milestone with its product Barhemsys® (amisulpride) injection. On January 1, 2024, Barhemsys will receive a unique, product-specific billing code (J-0184) from the Centers for Medicare & Medicaid Services (CMS), facilitating better access and separate reimbursement for the drug outside of surgical bundled payments. Barhemsys is the only FDA-approved medication for treating postoperative nausea and vomiting (PONV) in patients who have failed PONV prophylaxis, addressing a critical unmet medical need.
In addition to its marketed products, Eagle Pharmaceuticals boasts an extensive pipeline focusing on oncology and CNS/metabolic critical care. Noteworthy among these is the ready-to-dilute formulation of Pemfexy, used in treating non-small cell lung cancer and malignant pleural mesothelioma. Pemfexy's unique J-Code from CMS has earned it a 24% share in the non-340B pemetrexed market, reflecting its commercial success and innovation.
Financially, Eagle remains strong, with steady revenues from its commercialized products and a commitment to reporting accurate financial results. While the company has revised its 2023 guidance downward, it remains confident in the outlook for 2024, backed by ongoing development and new initiatives.
This strategic focus is further reinforced by Eagle’s robust intellectual property protections and recent litigation successes. The company is actively defending its patents against generic competitors, ensuring the continued commercial viability of its flagship products, Bendeka and Belrapzo.
With a team of dedicated professionals in research, development, clinical, and commercial operations, Eagle Pharmaceuticals is poised to make significant strides in the pharmaceutical industry. For the latest news and updates, visit their official website at www.eagleus.com.
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) has announced a settlement agreement with Dr. Reddy’s Laboratories regarding patent litigation related to its drug BENDEKA®. Under the terms of the settlement, Dr. Reddy’s can market its product starting November 17, 2027, with potential for earlier market entry under specific conditions. This agreement is confidential and subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice. This follows previous settlements with Hospira and Accord Healthcare regarding similar patent claims.
Eagle Pharmaceuticals reported Q4 2022 net income of $8.2 million, or $0.63 per share, compared to a loss of $6.2 million in Q4 2021. Total revenue for Q4 2022 was $60.7 million, an increase from $42.3 million year-over-year. For FY 2022, Eagle achieved net income of $35.6 million, up from a loss of $8.6 million in 2021, with total revenue rising to $316.6 million from $171.5 million. PEMFEXY® achieved $12.1 million in sales in Q4 2022, capturing a 6% market share. The FDA approved PEMFEXY for an additional indication, and the company plans to increase its share to 12% by Q1 2023. Eagle had $55.3 million in cash as of December 31, 2022.
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) announced that CEO Scott Tarriff and CFO Brian Cahill will participate in a fireside chat at the Barclays Global Healthcare Conference on March 15, 2023, at 2:35 PM ET. This event will take place in Miami, FL, and will be available via webcast. Eagle Pharmaceuticals is committed to innovation in medicines that enhance patients' lives, with a diverse product portfolio and a strong pipeline targeting critical areas in oncology and metabolic care.
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) will release its fourth quarter and full year 2022 financial results on March 13, 2023, before the market opens. CEO Scott Tarriff and CFO Brian Cahill will host a conference call at 8:30 a.m. ET to discuss the results. Investors can access the call toll-free at 800-445-7795 (U.S.) or 785-424-1789 (International). A replay will be available for two weeks, and the webcast will be archived for 30 days on the company's website.
Eagle specializes in developing innovative medicines and has a portfolio of commercialized products including vasopressin and BENDEKA®. The company focuses on addressing critical care and oncology needs.
Eagle Pharmaceuticals, Inc. (EGRX) reported a net income of $21.3 million for the year ending September 30, 2022, translating to $1.63 per diluted share. The company's adjusted EBITDA stood at $125.6 million, showing substantial growth from 2021. Eagle aims to double its share of the pemetrexed market with projected quarterly revenues of $8 million. The company anticipates an adjusted EBITDA of $74.0-$80.0 million and adjusted non-GAAP earnings per share of $4.20-$4.53 for 2023. Key product growth is expected, especially in PEMFEXY sales, post royalty adjustments.
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) announced that CEO Scott Tarriff and CFO Brian Cahill will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 10:30 AM PT/1:30 PM ET. The presentation will be available as a webcast for 30 days on the company’s website, allowing investors to access key insights into Eagle’s corporate strategies and product pipeline. The company is recognized for its innovative pharmaceutical solutions aimed at improving patient outcomes, with commercialized products across critical care and oncology.
FAQ
What is the current stock price of EAGLE PHARMS (EGRX)?
What is the market cap of EAGLE PHARMS (EGRX)?
What products does Eagle Pharmaceuticals offer?
What recent regulatory updates have impacted Eagle Pharmaceuticals?
What areas does Eagle Pharmaceuticals focus on?
How is Eagle Pharmaceuticals performing financially?
What is Pemfexy used for?
What distinguishes Barhemsys in the market?
What is Eagle Pharmaceuticals' approach to intellectual property?
What is the focus of Eagle Pharmaceuticals' pipeline?
How can I stay updated on Eagle Pharmaceuticals' latest news?
What is the impact of Eagle's litigation efforts?
